(Reuters) - The deal values Digene shares at $61.25, a 37 percent premium to its closing price on the Nasdaq on Friday, the companies said in a joint statement.
Netherlands-based Qiagen's acquisition comes as major drug makers pursue vaccines for cervical cancer, which is the second most common cancer in women under 40.
Read more at Reuters.com Business News
Netherlands-based Qiagen's acquisition comes as major drug makers pursue vaccines for cervical cancer, which is the second most common cancer in women under 40.
Read more at Reuters.com Business News
No comments:
Post a Comment